UHSM CTP DOH Q2 2016 2017 Performance in initiaing Report

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited ?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay corresponded to:
86492	14/YH/1199	153953	NHS Permission	GALACTIC: GA101 (obinutuzumab) monoClonal Antibody as Consolidation Therapy In CLL	16/09/2015	02/10/2015	Yes	19/10/2015	16	17	33	Yes							Please Select...														Please Select...
86493	14/YH/1162	154011	NHS Permission	A study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing sterotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered Higher risk of complication from surgical resection	25/09/2015	09/10/2015	Yes	19/02/2016	14	133	147	No							Please Select...							Y						Patients screened but no eligible patients identified.	Neither
86494	15/YH/0178	174447	NHS Permission	A Phase 3, Randomized, Double-Blinded, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in combination with Ivacaftor in subjects aged 12 years and older with Cyctic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a second CFTR Allele with a gating defect that is clinically demonstrated to be Ivacaftor responsive (Vertex 109)	05/10/2015	12/10/2015	Yes	26/10/2015	7	14	21	Yes							Please Select...														Please Select...
86495	14/SC/0171	120104	NHS Permission	A phase III, double-blind, placebo- controlled, randomised trial assessing the effects of asprin on disease recurrence and survival after primary therapy in common non- metastatic solid tumours. (add aspirin)	15/10/2015	22/10/2015	Yes	14/12/2015	7	53	60	Yes							Please Select...														Please Select...
86496	14/LO/2195	165351	NHS Permission	Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer (ARB)	20/10/2015	26/10/2015	Yes	30/11/2015	6	35	41	Yes							Please Select...														Please Select...
86497	15/LO/1289	181953	NHS Permission	An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures	29/10/2015	02/11/2015	Yes	12/05/2016	4	192	196	No							Please Select...							Y						Patients screened but no eligible patients identified. Strict patient eligibility criteria; we are using the 30% of patients seen who are resistant to Clopidogrel This makes the trial very difficult to recruit to.	Neither
86498	15/NW/0032	151852	NHS Permission	Imaging cerebral neuroinflammation in acute and chronic cerebrovascular disease: a predictor of outcome and biomarker for guidijng treatment (IN-CVD)	01/10/2015	05/11/2015	Yes	10/11/2015	35	5	40	Yes							Please Select...														Please Select...
86499	15/EE/0130	170557	NHS Permission	A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment.	27/10/2015	09/11/2015	Yes	05/07/2016	13	239	252	No							Please Select...							Y						Patients screened but no eligible patients identified	Neither
86500	14/YH/0128	150031	NHS Permission	Sacral nerve stimulation versus the FENIX magnetic sphincter augmentation for adult faecal incontinence: a Randomised Investigation (SaFaRI)	09/11/2015	10/11/2015	Yes	10/02/2016	1	92	93	No							Please Select...								Y					Eligible patients seen chose not to participate in the study, other options have been available to the patients and they do not want such an evasive procedure	Neither
86501	15/NW/0724	173790	NHS Permission	Evaluation of the fast fill technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter [PI - Mr Nicholas Heywood]	28/10/2015	11/11/2015	Yes	11/11/2015	14	0	14	Yes							Please Select...														Please Select...
86502	15/LO/0699	173824	NHS Permission	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function	12/11/2015	19/11/2015	Yes	18/12/2015	7	29	36	Yes							Please Select...														Please Select...
86503	11/SS/0100	84669	NHS Permission	Fluoxetine Or Control Under Supervision	22/10/2015	25/11/2015	Yes	19/01/2016	34	55	89	No							Please Select...		Y					Y						The main reason for NHS to FPR being over 70 days is ' F - No eligble patients seen - strict patient eligibility criteria' the reason for this delay corresponds to 'neither'. The VRA to NHS was over 30 days due to 'A - local review not completed in time' the reason for this delay corresponds to NHS provider.	NHS Provider
86504	14/WS/1106	157143	NHS Permission	A Comparison of Fractional Flow ReserveGuided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients with Multivessel Coronary Artery Disease: The FAME 3 Trial	30/11/2015	02/12/2015	Yes	01/02/2016	2	61	63	Yes							Please Select...														Please Select...
86505	13/LO/1481	132746	NHS Permission	A study to determine if it is feasible to recruit into a randomised trial comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma. (MARS 2)	02/12/2015	07/12/2015	Yes	05/01/2016	5	29	34	Yes							Please Select...														Please Select...
86506	11/EE/0347	75112	NHS Permission	The 2nd European Carotid Surgery Trial (ECST2)	20/10/2015	10/12/2015	No		51			No							Please Select...		Y					Y						The main reason for VRA to FPR being over 70 days is 'F - No eligble patients seen and strict patient eligibility criteria' the reason for this delay corresponds to 'neither'. The VRA to NHS was over 30 days due to 'A - local review not completed in time' the reason for this delay corresponds to 'NHS provider'.	NHS Provider
86507	15/LO/0833	165266	NHS Permission	FEASIBILITY of IBIS 3. An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment	11/01/2016	12/01/2016	No		1			No							Please Select...					Y								sponsor delay in provision of study documentation and provision of IMP/device/equipment	Sponsor
86508	15/NW/0306	161393	NHS Permission	Does intraoperative use of the MarginProbe device reduce the need for further reexcision procedures after conservation surgery for breast cancer? (margin probe)	21/03/2016	22/03/2016	Yes	29/04/2016	1	38	39	Yes							Please Select...														Please Select...
86509	15/NW/0478	172209	NHS Permission	A pilot prevention study of the effects of the antiprogestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk	22/01/2016	22/01/2016	Yes	29/03/2016	0	67	67	Yes							Please Select...														Please Select...
86510	15/WM/0331	184594	NHS Permission	The HeartMate III PostMarket Registry	08/12/2015	14/01/2016	Yes	14/01/2016	37	0	37	Yes							Please Select...														Please Select...
86511	15/SC/0115	167694	NHS Permission	A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus. (HARMONY)	12/01/2016	18/01/2016	Yes	10/02/2016	6	23	29	Yes							Please Select...														Please Select...
86512	15/YH/0309	182015	NHS Permission	A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 104-week Long - term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered with Dapagliflozin in Combination with Metformin Compared to Glimepiride in Combination with Metformin in Adult Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone.	25/01/2016	29/01/2016	No		4			No							Please Select...				Y									Study closed by sponsor at all sites	Sponsor
86513	15/EE/0405	189187	NHS Permission	A Randomized, DoubleBlind, PlaceboControlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients with Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDLC Lowering Therapy.	25/02/2016	26/02/2016	Yes	12/05/2016	1	76	77	No							Please Select...		Y					Y						Study wide review not completed in time by NHS provider - SSI form was submitted early due to new HRA process. NHS to FPR is over 40 days delay is due to ' E unexpected long term staff absence'	NHS Provider
86514	15/LO/2102	189922	NHS Permission	A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix ? Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries	05/02/2016	11/02/2016	Yes	04/07/2016	6	144	150	No							Please Select...							Y						Patients screened but no eligible patients identified	Neither

86515	15/NW/0821	191169	NHS Permission	Calprotectin in IBD ORI-CAL-01 (OriCol) - Comparison of Calprotectin Levels in Stool and Rectal Mucus in Subjects with Suspected or Confirmed Inflammatory Bowel Disease	25/01/2016	26/01/2016	Yes	17/02/2016	1	22	23	Yes							Please Select...														Please Select...
86516	15/NW/0916	188456	NHS Permission	Evaluation of the Recto-anal Inhibitory Reflex (RAIR) using Anal Acoustic Reflectometry (AAR)	10/02/2016	11/02/2016	Yes	25/02/2016	1	14	15	Yes							Please Select...														Please Select...
86517	15/NW/0897	178630	NHS Permission	Investigating the role of portable VR intervention in phantom limb pain.	02/03/2016	03/03/2016	Yes	17/03/2016	1	14	15	Yes							Please Select...														Please Select...
86518	15/LO/1419	183975	NHS Permission	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)	10/02/2016	23/03/2016	Yes	06/04/2016	42	14	56	Yes							Please Select...														Please Select...
86519	14/SW/0075	151804	NHS Permission	A Randomised Controlled Trial Evaluating the Efficacy of Indwelling Pleural Catheters in Persistent Non Malignant Symptomatic Pleural Effusions	18/01/2016	19/01/2016	Yes	04/05/2016	1	106	107	No							Please Select...						Y					low recruitment target - this is a niche study and only one patient is expected per year.	Neither
86520	15/NI/0158	182421	NHS Permission	A RANDOMISED PRAGMATIC TRIAL OF CORTICOSTEROID OPTIMISATION IN SEVERE ASTHMA USING A COMPOSITE BIOMARKER ALGORITHM TO ADJUST CORTICOSTEROID DOSE VERSUS STANDARD CARE	21/01/2016	22/01/2016	Yes	27/04/2016	1	96	97	No							Please Select...						Y					Strict patient eligibility criteria	Neither
86521	15/EM/0309	184678	NHS Permission	A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two doses of nebulised budesonide delivered by the VR475 Inhalation System, with an open-label comparison to conventionally nebulised budesonide, in patients with uncontrolled asthma despite treatment with high dose inhaled corticosteroid and at least a second controller (GINA Step 4) and those receiving oral corticosteroid (GINA Step 5)	02/02/2016	04/02/2016	Yes	05/04/2016	2	61	63	Yes							Please Select...														Please Select...
86522	15/NW/0787	191007	NHS Permission	Investigating Neuronal responses by assessing capsaicin evoked Cough responses in an allergen challenge model of Asthma (INCA)	05/02/2016	08/02/2016	Yes	16/02/2016	3	8	11	Yes							Please Select...														Please Select...
86523	15/SW/0248	186033	NHS Permission	A Phase 3, Openlabel, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation	19/02/2016	22/02/2016	Yes	29/02/2016	3	7	10	Yes							Please Select...														Please Select...
86524	15/NW/0697	183760	NHS Permission	A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo? compared to standard of care insulin for initiating basal insulin in insulin na?ve patients with uncontrolled type 2 diabetes mellitus, with 6-month extension.	22/03/2016	31/03/2016	Yes	31/05/2016	9	61	70	Yes							Please Select...														Please Select...
86525	15/NW/0698	183781	NHS Permission	A twenty six week, randomized, openlabel, 2 arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo? compared to standard of care insulin, in basal insulin treated patients with uncontrolled type 2 diabetes mellitus, with six month extension.	14/03/2016	31/03/2016	Yes	25/05/2016	17	55	72	No							Please Select...		Y			Y							Study wide review not completed in time by NHS provider - SSI form was submitted early due to new HRA process. NHS to FPR is over 40 days delay is due to ' E unexpected long term staff absence'	NHS Provider
86526	15/WA/0241	183747	NHS Permission	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two	22/03/2016	29/03/2016	No		7			No							Please Select...				Y							sponsor delay in provision of equipment	Sponsor
86527	16/NW/0033	192134	NHS Permission	Correlation of Anal Acoustic Reflectometry parameters with degree of Rectal Intussusception and Prolapse	16/03/2016	31/03/2016	Yes	06/04/2016	15	6	21	Yes							Please Select...														Please Select...
86528	14/ss/1096	164274	NHS Permission	Rapid Assessment of Potential Ischaemic Heart Disease with CTCA - The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department or Medical Assessment Unit with suspected or confirmed Acute Coronary Syndrome (The RAPID-CTCA Trial).	31/03/2016	12/05/2016	Yes	27/06/2016	42	46	88	No							Please Select...		Y				Y						VRA to NHS over 30 days due to 'A Study wide review not completed in time by NHS provider' - SSI form was submitted early due to new HRA process. NHS to FPR is over 40 days delay is due to ' F Patients screened but no eligible patients identified'	NHS Provider
86529	15/LO/0732	172401	NHS Permission	Pragmatic randomised trial of low versus high volume initiated trans-anal irrigation therapy in adults with chronic constipation (CapaCITY 2)	23/03/2016	11/04/2016	No		19			No							Please Select...						Y					Patients screened but no patients identified.	Neither
86530	16/EM/0037	196490	NHS Permission	A Multicenter, Randomized, Double-Blind, Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients with Radiographic Axial Spondyloarthritis	23/03/2016	25/04/2016	Yes	17/06/2016	33	53	86	No							Please Select...		Y				Y						VRA to NHS was over 30 days due to 'A - study wide review not completed in time by NHS provider' this delay corresponds to 'NHS provider'. NHS to FPR is over 40 days due to 'F - strict patient eligibility criteria/low recruitment target' this delay corresponds to 'neither'	NHS Provider
86531	15/LO/0609	171006	NHS Permission	Stepped Wedge Randomised Trial of Laparoscopic Ventral Mesh Rectopexy in Adults with Chronic Constipation (CapaCITY 3)	23/03/2016	04/05/2016	No		42			No							Please Select...		Y				Y					VRA to NHS was over 30 days due to 'A - study wide review not completed in time by NHS provider' SSI was submitted early and reason for this delay corresponds to 'NHS provider'. NHS to FPR is over 40 days due to ' F - patients screened but no eligible patients identified' reason for delay corresponds to 'neither'.	NHS Provider
86532	15/YH/0531	166392	NHS Permission	A Psychosocial Therapy to Benefit People with Parkinson?s-related Dementia: A Feasibility and Exploratory Pilot Study of Individual Cognitive Stimulation Therapy (INVEST).	29/03/2016	10/05/2016	Yes	02/06/2016	42	23	65	Yes							Please Select...														Please Select...
86533	16/ES/0001	193859	NHS Permission	REVOLVE - A Phase 3, randomized, double-blind, placebo-controlled, multicentre study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn?s Disease	23/03/2016	24/06/2016	No		93			No							Please Select...				Y							Sponsor delayed site initiation visit.	Sponsor
86534	15/NW/0406	167520	NHS Permission	Thrombin Inhibition Preoperatively in Early Breast Cancer (TIP)	21/01/2016	25/04/2016	Yes	25/05/2016	95	30	125	No							Please Select...				Y							Sponsor delay through research application amendments , old version of SmPC submitted to REC & MHRA at time of initial submission.	Sponsor
86535	15/LO/1500	187068	NHS Permission	BI 1199.229 - Investigation of drug-drug interaction between nintedanib and pirfenidone in patients with IPF (an open label, multiple-dose, two group study followed by nintedanib open label treatment)	29/03/2016	19/04/2016	Yes	03/05/2016	21	14	35	Yes							Please Select...														Please Select...
86536	16/SC/0018	191267	NHS Permission	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis [Empire (CTX-4430)]	23/03/2016	26/04/2016	Yes	06/06/2016	34	41	75	No							Please Select...						Y			Y		VRA to FPR is over 70 days delay reason is 'F - patients screened but no eligible patients identified'. VRA to NHS is over 30 days delay reason is 'H - Contracting / costing delays' the contact person for liaising about the contract and costings changed right at the end and the new person asked for clarifications for some things that were agreed already	Sponsor
86537	16/SC/0089	196789	NHS Permission	The REST Study - pRotective vEntilation with ven-venouS lung assisT in respiratory failure	31/03/2016	30/06/2016	No		91			No							Please Select...				Y							Sponsor delayed confirmation of study open to recruitment at site	Sponsor
86538	15/EM/0473	187884	NHS Permission	A randomized, open-label, active-controlled, Phase II study of intravenous anetumabravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastaticmalignant pleural mesothelioma overexpressing mesothelin and progressed on first lineplatinum/pemetrexed-based chemotherapy (Bayer 15743)	11/03/2016	07/04/2016	Yes	11/04/2016	27	4	31	Yes							Please Select...														Please Select...
86539	15/NW/0747	186601	NHS Permission	BIOSIMILAR A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin? plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer	08/03/2016	20/04/2016	No		43			No							Please Select...				Y							sponsor delay in provision of study documentation and provision of equipment etc	Sponsor
86540	15/SC/0600	187954	NHS Permission	The Efficacy of Sonographic and Biological Pleurodesis Indicators of Malignant Pleural Effusion (SIMPLE) - a randomised trial	29/03/2016	16/06/2016	Yes	22/08/2016	79	67	146	No							Please Select...		Y				Y					VRA to NHS over 30 days due to 'A - Study wide review not completed in time by NHS provider' SSI was submitted early due to new HRA process. this delay corresponds to 'nhs provider'. NHS to FPR delay due to 'F - patients screened but no eligible patients identified' delay corresponds to 'neither'	NHS Provider

86541	15/EE/0298	186974	NHS Permission	LuCID: Lung Cancer Indicator Detection	24/03/2016	23/06/2016	Yes	07/07/2016	91	14	105	No							Please Select...		Y			Y							VRA to NHS over 30 days due to 'A - Study wide review not completed in time by NHS provider' SSI was submitted early due to new HRA process. this delay corresponds to 'nhs provider'. Also 'D - Sponsor delayed confirmation of study open to recruitment at site' this delay corresponds to 'sponsor'.	Sponsor
86676	15/LO/1079	177212	NHS Permission	A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem? Therapy in Subjects with Acute Respiratory Distress Syndrome (B04-01 CATAPULT)	29/03/2016	05/07/2016	Yes	29/09/2016	98	86	184	No							Please Select...					Y		Y					VRA to FPR is over 70 days delay reason is 'F - Patients screened but no eligible patients identified / Strict patient eligibility criteria' VRA to NHS is over 30 days delay reason is 'D - Sponsor delay in provision of study documentation (insurance renewal)'	Sponsor
86677	16/NW/0089	165834	NHS Permission	A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrome with Constipation.	23/03/2016	21/09/2016	No		182			No							Please Select...		Y										VRA to NHS was over 30 days due to 'A - study wide review not completed in time by NHS provider' SSI was submitted early due to new HRA process. and reason for this delay corresponds to 'NHS provider'	NHS Provider
86678	16/NE/0014	192732	HRA Approval	AF219-012 12-Week Study in Subjects with Refractory Chronic Cough			Yes	10/05/2016				No		16/10/2015	22/12/2015	02/03/2016	07/04/2016	13/04/2016	Please Select...	21/04/2016	Y									Study wide review not completed in time by NHS provider - SSI form was submitted early due to new HRA process.	NHS Provider
86679	15/NW/0464	?178997	HRA Approval	Assessment of communication and speech via Blue Line Ultra ?Suctionaid? (BLUS) tracheostomy tubes for Intensive Care Patients			Yes	24/08/2016				yes		18/05/2016	03/08/2016	03/08/2016	05/08/2016	05/08/2016	Please Select...	05/08/2016											Please Select...
86680	16/LO/0793	203066	HRA Approval	Effect of nintedanib on biomarkers of ECM turnover in patients with IPF and limited FVC impairment (BI1199.227)			Yes	02/08/2016				No		08/03/2016	09/05/2016	28/06/2016	07/07/2016	11/07/2016	Please Select...	22/06/2016				Y						Sponsor delayed confirmation of study open to recruitment at site until after the target date	Sponsor
86681	15/NW/0825	172162	HRA Approval	Introduction of breast cancer prevention with tamoxifen and raloxifene for women at increased risk of breast cancer (Tara Prev)			Yes	14/07/2016				yes		03/05/2016	19/05/2016	19/05/2016	01/07/2016	01/07/2016	Please Select...	01/07/2016											Please Select...
86682	13/WS/0119	117753	HRA Approval	A randomised, double blind, placebo-controlled, parallel group, Trial of low-dose adjunctive alTeplase during prIMary PCI (T-TIME)			Yes	27/09/2016				No		21/04/2016	01/06/2016	01/06/2016	21/06/2016	27/06/2016	Please Select...	04/07/2016					Y					Patients screened but no eligible patients identified A recent amendment to the study by the sponsor has enabled more patients to be recruited to the study.	Neither
86683	16/NW/0057	191883	HRA Approval	RCT of a targeted distributed toothpaste & toothbrushing programme to reduce paediatric general anaesthetic operations for dental procedures in young children from at risk families (Tiger Teeth)			Yes	21/09/2016				No		31/03/2016	04/07/2016	22/06/2016	26/08/2016	13/09/2016	Please Select...	14/09/2016				Y						Sponsor Delays, Sponsor delayed confirmation of study open to recruitment at site (i.e., green light)	Sponsor
86684	14/YH/0085	126738	HRA Approval	Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab (FLAIR)			Yes	06/10/2016				No		12/02/2016	15/06/2016	15/06/2016	06/07/2016	03/08/2016	Please Select...	03/08/2016						Y				Eligible patients seen chose not to participate in study for Personal Reasons	Neither